Ophthalmology

According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.

ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

The investigators believe that, based on their findings, the impact of COVID-19 on the autonomous nervous system warrants further prospective studies and assessment of pupillary function might be a useful test for determining autonomic dysfunction.

Imaging study revealed specific retinal and choroidal changes associated with the disease.

Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.

Investigators have cited the need for pharmacologic and non-pharmacologic interventions to improve the ongoing burden after hospitalization for COVID-19.

In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.

Recent literature review reveals dearth of data, highlights need for more research.

The difference in visual acuities based on CST fluctuations in these patients with diabetic macular edema remained significant.

The newly formed Bespoke Gene Therapy Consortium (BGTC) will team up to beat rare diseases that are currently using gene therapy.

Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.

Current options, challenges in developing novel therapies.

Electronic health records may be the future of practice management.

Under terms of the agreement, ImprimisRx to assume full responsibility for US sales and marketing activities for Dexycu.

Dr. McDonnell highlights inspiring moments from the 2021 annual meeting of the American Academy of Ophthalmology, along with a look ahead to next year’s conference in Chicago.

Novartis has revealed the first interpretable results from year two (week 100) of the Phase III KESTREL study.

Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.

A pilot study tests the technology to obtain remote fundus imaging of patients.

Retinal and choroidal changes were observed in study.

Peter J. McDonnell, MD, shares some of many highlights from this year’s annual meeting of the American Academy of Ophthalmology in New Orleans.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Using its proprietary software, the company has been able to create models in a fraction of the time typically needed for fitting one.

The company’s re:Vive technology features 6 vision diagnostic exams, supported by 5 reimbursable CPT codes in 1 wearable solution.

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

EyeCon co-chairs Peter J. McDonnell, MD, and Oluwatosin U. Smith, MD, discuss the virtual conference and its relevance to ophthalmologists across the country.